Designed around the way
your specialty works.
Longitudinal metabolic record combining laboratory control, device-generated glucose, complications and patient goals.
Classify diabetes and metabolic conditions, capture onset, treatment history, nutrition, activity and relevant psychosocial context.
Review glucose patterns alongside medicines, meals, illness and hypoglycaemic events; record shared goals and education.
Track renal, eye, foot, cardiovascular and neuropathy assessments with referrals and overdue review worklists.
Support obesity/metabolic care, connected-device onboarding, data-sharing consent and transitions such as pregnancy or paediatric-to-adult care.
Diagnosis coverage and clinical records
Type 1/type 2 and other specified diabetes; gestational diabetes linked to MFM; obesity; dyslipidaemia; metabolic syndrome; hypoglycaemia and diabetes complications. Do not classify diabetes solely from device data or silently apply adult rules to pregnancy/children.
Measurements that give the record meaning
| Measurement | Units / representation | Clinical context |
|---|---|---|
| HbA1c | % or mmol/mol | Assay/date and factors affecting interpretation |
| Glucose | mmol/L or mg/dL | Sensor versus capillary/venous, timestamp and meal context |
| CGM summary | % time; mean; variability | Target range, reporting window, data sufficiency and algorithm |
| Weight/BMI/waist | kg; kg/m²; cm | Measurement dates and longitudinal goals |
| Renal screening | eGFR; urine albumin/creatinine ratio | Equation, units and sample |
| Lipids/BP | mmol/L or mg/dL; mmHg | Analyte, fasting context and technique |
| Insulin/therapy events | product units; timestamps | Device versus reported delivery, formulation and method |
Equipment and integration plans
- Glucose meters, CGM, connected pens and pump portals → authorized manufacturer APIs or validated exports. Dexcom v3 provides developer endpoints; commercial access and latency need confirmation.
- AID/pump control remains within approved systems; imported glucose must never directly trigger unvalidated insulin commands.
Connections require an approved interface and testing against the installed manufacturer, model and software. Listed equipment is a candidate integration target.
Explore equipment & roboticsReporting and meaningful outcomes
Screening completion, patient-specific glycaemic trend, CGM data coverage, hypoglycaemia follow-up and goal review; retain target-range definitions and population context.
Development scope and clinical validation
Initial scope
Metabolic review, labs, complication register, education and manual device report attachment.
Advanced scope
Authorized CGM/pen/pump data and validated standardized summaries.
Example acceptance scenarios
- Unit conversion and timezone/daylight changes must preserve original values/times and prevent duplicate CGM points.
- CGM gaps must be visible; incomplete coverage cannot be marketed or interpreted as continuous monitoring.
Research foundations
- ADA Standards of Care 2026, section 7: diabetes technology ↗
- Dexcom API v3 endpoint documentation ↗
- HL7 FHIR R4 Observation ↗
Research snapshot: 23 September 2026. References inform the proposed design; they do not certify FertPro or establish device compatibility. Diagnosis lists and measurement groups are not treatment protocols.